Compare Incyte Corporation (INCY) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Quanta Services Inc — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while Quanta Services Inc trades at $682.1 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 4.1× Incyte Corporation's market cap, and Quanta Services Inc pays a 0.07% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PWR | |
|---|---|---|
Market Cap | $24.54B | $100.82B |
Sector | Health | Industrials |
52-Week High | $129.93 | $785.24 |
52-Week Low | $81.66 | $372.50 |
Enterprise Value | $20.04B | $106.91B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
PWR trades at $677.91, up 2.58% today, with strong technical momentum above key support at $664. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating expectations by 28%, revenue growth accelerating to $28.48B in 2025, and a record backlog supporting raised 2026 guidance. Analyst sentiment remains overwhelmingly positive with 72% buy ratings and a $809.75 consensus target.
PWR offers compelling growth exposure to infrastructure demand, particularly in power and data centers, but faces valuation concerns with a P/E of 76.7x. Near-term risks include execution on large projects and macroeconomic sensitivity, while institutional accumulation and strong cash flow generation support the bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
